Novartis CEO: Deals possible in diagnostics, vaccines
Novartis AG CEO Daniel Vasella (photo) concedes that his company is going through a rough stage, but insists that a robust pipeline of new therapies will lead the drug giant to better days. In an interview with the Swiss weekly Sonntag, Vasella said Novartis' recent deal to buy a stake in Alcon for $11 billion represented a move to diversify the business. And more deals may lie ahead.
"Medium-sized acquisitions, which are not planned at the moment, would certainly still be possible," Vasella told the pub. "Diagnostics is a business field worth expanding, so are vaccines and generics."
Alcon, meanwhile, plans to build a manufacturing facility in Singapore to supply pharmaceuticals to the Asian market. Singapore has been swiftly growing as a manufacturing hub for the region.
- read the AFX report
Related Articles:
Vasella touts Novartis' diversification
Novartis taps new U.S. pharma chief
Novartis discovery chief departs in shakeup
CEO: Novartis plans big restructuring
Novartis pledges $39B for Alcon
Cash-rich Novartis CEO mulls biotech buyouts
Be the first to comment
More stories about Vaccines restructuring pharmaceuticals Novartis Mergers and Acqusitions Daniel Vasella buyouts Alcon
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
